欧洲血尿治疗市场预测至 2028 年 - COVID-19 影响和按治疗(药物、疗法等)、适应症(尿路感染、肾结石、尿道炎、血癌、膀胱结石、前列腺癌、膀胱炎、创伤、剧烈运动、多囊肾、子宫内膜异位症和月经)、类型(肉眼血尿、显微镜下血尿、特发性血尿和慢跑者血尿)、最终用户(医院、诊所和门诊手术中心等)

Historic Data: 2019-2020   |   Base Year: 2021   |   Forecast Period: 2022-2028


No. of Pages: 177    |    Report Code: TIPRE00026250    |    Category: Life Sciences

Europe Hematuria Treatment Market

市场介绍

血尿是一种在尿液中发现血液的疾病。一般来说,尿液中不含红细胞,因此可能会导致严重的问题,还可能导致肾结石、尿路感染和其他遗传性疾病。

此外,血尿的患病率很高预计相关迹象将在预测期内促进市场增长。然而,相关适应症的未确诊病例限制了欧洲血尿治疗市场的增长。

许多患者报告在入院和住院期间出现进行性急性肾损伤 (AKI),轻度蛋白尿和血尿症状,这与 COVID-19 住院患者的不良临床结果相关。据报道,蛋白尿和血尿在 COVID-19 中的患病率甚至比 AKI 更高。中国的回顾性研究报告称,蛋白尿和血尿与 COVID-19 相关,且死亡率较高。此外,根据欧洲肾脏协会(ERACODA)2020年3月建立的COVID19数据库,大约25%的肾移植患者被诊断出患有冠状病毒。因此,预计新冠病毒阳性患者的增加更有可能接受肾脏疾病治疗。

市场概况和动态

欧洲血尿治疗市场预计将从2021年的2.705亿美元增至2028年的3.138亿美元;预计2021年至2028年复合年增长率为2.1%。该地区的患者大多更喜欢家庭护理服务。可穿戴和便携式医疗设备具有改善治疗的巨大潜力,可以让患者在透析过程中继续进行日常活动。例如,家庭透析为患者的工作和生活方式安排提供了更大的灵活性。此外,与传统透析相比,家庭血液透析的整体程序大大简化。因此,可穿戴和植入设备可以为患者在治疗期间提供工作和日常活动的自由。这种先进的治疗替代方案可能会在未来几年推动欧洲血尿治疗市场的发展。

关键细分市场

< /span>

从类型来看,肉眼血尿细分市场在2020年欧洲血尿治疗市场中占据最大份额。从治疗来看,药物细分市场占据最大份额。 2020年欧洲血尿治疗市场。从适应症来看,尿路感染细分市场占2020年欧洲血尿治疗市场的最大份额。从最终用户来看,医院细分市场占欧洲血尿治疗市场的最大份额2020年治疗市场。

主要来源和上市公司

<准备本欧洲血尿治疗市场报告时参考的一些主要一手和二手来源包括公司网站、年度报告、财务报告、国家政府文件和统计数据库等。报告中列出的主要公司包括阿斯利康、百时美施贵宝公司、F. HOFFMANN-LA ROCHE LTD.、葛兰素史克公司、杨森制药、默沙东制药公司和默沙东制药公司。 Co., Inc.、Novartis AG、Pfizer Inc.、Sun Pharmaceutical Industries Ltd 和 Boehringer Ingelheim International GmbH。

购买报告的理由

  • 了解欧洲血尿治疗市场格局并确定细分市场可能会保证丰厚的回报
  • 了解不断变化的市场格局并在竞争中保持领先
  • 高效通过确定最有可能销售前景的细分市场,规划欧洲血尿治疗市场的并购和合作伙伴关系
  • 通过对市场的敏锐和全面分析,做出明智的业务决策各个细分市场的业绩
  • 获取2021年-2028年基于各个细分市场的欧洲血尿治疗市场的市场收入预测

欧洲血尿治疗市场细分

作者

治疗

  • 药物
  • 疗法
  • 其他 

按指示

  • 尿路感染
  • 肾结石
  • 尿道炎
  • 血癌
  • 膀胱结石
  • 前列腺癌
  • 膀胱炎
  • 外伤
  • 剧烈运动< /span>
  • 多囊肾
  • 子宫内膜异位症
  • 月经

类型

  • 肉眼血尿
  • 显微镜下血尿
  • 特发性血尿
  • < span>慢跑者血尿

最终用户

< ul>
  • 医院
  • 诊所
  • 门诊手术中心(ASC)
  • 其他
  • 按国家/地区

    • 欧洲
      • 德国
      • 英国
      • 法国
      • 西班牙
      • 意大利
      • 欧洲其他地区< /li>

    提及的公司

    • < span>阿斯利康
    • 百时美施贵宝公司
    • F. HOFFMANN-LA ROCHE LTD.
    • 葛兰素史克公司
    • 杨森制药
    • 默克公司有限公司
    • 诺华公司
    • 辉瑞公司
    • < span>太阳制药工业有限公司
    • 勃林格殷格翰国际有限公司


    Europe Hematuria Treatment Strategic Insights

    Strategic insights for Europe Hematuria Treatment involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

    strategic-framework/europe-hematuria-treatment-market-strategic-framework.webp
    Get more information on this report

    Europe Hematuria Treatment Report Scope

    Report Attribute Details
    Market size in 2021 US$ 270.5 Million
    Market Size by 2028 US$ 313.8 Million
    Global CAGR (2021 - 2028) 2.1%
    Historical Data 2019-2020
    Forecast period 2022-2028
    Segments Covered By 治疗
    • 药物
    • 疗法
    By 适应症
    • 泌尿道感染
    • 肾结石
    • 尿道炎
    • 血癌
    • 膀胱结石
    • 前列腺癌
    • 膀胱炎
    • 创伤
    • 剧烈运动
    • 多囊肾病
    • 子宫内膜异位症
    • 月经
    By 类型
    • 肉眼血尿
    • 显微镜下血尿
    • 特发性血尿
    • 慢跑者血尿
    By 最终用户
    • 医院
    • 诊所
    • 门诊手术中心
    Regions and Countries Covered 欧洲
    • 英国
    • 德国
    • 法国
    • 俄罗斯
    • 意大利
    • 欧洲其他地区
    Market leaders and key company profiles
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • F. HOFFMANN-LA ROCHE LTD.
  • GlaxoSmithKline plc.
  • Janssen Pharmaceuticals
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd
  • Boehringer Ingelheim International GmbH
  • Get more information on this report

    Europe Hematuria Treatment Regional Insights

    The regional scope of Europe Hematuria Treatment refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/europe-hematuria-treatment-market-geography.webp
    Get more information on this report

    The List of Companies - Europe Hematuria Treatment Market

    1. AstraZeneca
    2. Bristol-Myers Squibb Company
    3. F. HOFFMANN-LA ROCHE LTD.
    4. GlaxoSmithKline plc.
    5. Janssen Pharmaceuticals
    6. Merck & Co., Inc.
    7. Novartis AG
    8. Pfizer Inc.
    9. Sun Pharmaceutical Industries Ltd
    10. Boehringer Ingelheim International GmbH
    Frequently Asked Questions
    How big is the Europe Hematuria Treatment Market?

    The Europe Hematuria Treatment Market is valued at US$ 270.5 Million in 2021, it is projected to reach US$ 313.8 Million by 2028.

    What is the CAGR for Europe Hematuria Treatment Market by (2021 - 2028)?

    As per our report Europe Hematuria Treatment Market, the market size is valued at US$ 270.5 Million in 2021, projecting it to reach US$ 313.8 Million by 2028. This translates to a CAGR of approximately 2.1% during the forecast period.

    What segments are covered in this report?

    The Europe Hematuria Treatment Market report typically cover these key segments-

  • 治疗 (药物, 疗法)
  • 适应症 (泌尿道感染, 肾结石, 尿道炎, 血癌, 膀胱结石, 前列腺癌, 膀胱炎, 创伤, 剧烈运动, 多囊肾病, 子宫内膜异位症, 月经)
  • 类型 (肉眼血尿, 显微镜下血尿, 特发性血尿, 慢跑者血尿)
  • What is the historic period, base year, and forecast period taken for Europe Hematuria Treatment Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Hematuria Treatment Market report:

  • Historic Period : 2019-2020
  • Base Year : 2021
  • Forecast Period : 2022-2028
  • Who are the major players in Europe Hematuria Treatment Market?

    The Europe Hematuria Treatment Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • AstraZeneca
  • Bristol-Myers Squibb Company
  • F. HOFFMANN-LA ROCHE LTD.
  • GlaxoSmithKline plc.
  • Janssen Pharmaceuticals
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd
  • Boehringer Ingelheim International GmbH
  • Who should buy this report?

    The Europe Hematuria Treatment Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Europe Hematuria Treatment Market value chain can benefit from the information contained in a comprehensive market report.